Hansoh-backed Avere agrees to merge with NextCure in all-stock deal - NCNA News | RalliesHansoh-backed Avere agrees to merge with NextCure in all-stock deal
N
NCNA• Avere to merge into NextCure in all-stock deal
- Avere Therapeutics agreed to merge into Nasdaq-listed NextCure in an all-stock deal, with closing targeted for 2H 2026.
- The combined company is expected to operate as Avere Therapeutics and trade under ticker AVRX.
- Hansoh Pharmaceutical granted Avere a global ex-China license for HS-20118 (AVR-001), with up to USD 120 million upfront.
- Additional consideration includes up to USD 2.18 billion in milestones and mid-single to low-double digit royalties on sales.
- Hansoh also subscribed for Avere convertible notes in a private placement; post-close stake seen at 30%-40% fully diluted.
